AVRO - AVROBIO, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Cambridge,
United States
Type: Equity
AVRO price evolution
AVRO
| (in millions $) | 1 May 2023 | 31 Jan 2023 | 30 Sep 2022 | 30 Jun 2022 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $72.33 | $92.85 | $116.46 | $132.9 |
| Short term investments | ||||
| Net receivables | $0.27 | $2.98 | $2.96 | |
| Inventory | ||||
| Total current assets | $77.25 | $99.96 | $126.23 | $142.08 |
| Long term investments | $0.28 | |||
| Property, plant & equipment | $5.43 | $3.95 | $3.22 | $3.62 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $5.75 | $3.99 | $3.26 | $4.16 |
| Total investments | $0.28 | |||
| Total assets | $83 | $103.95 | $129.5 | $146.24 |
| Current liabilities | ||||
| Accounts payable | $0.59 | $0.38 | $1.81 | $0.03 |
| Deferred revenue | ||||
| Short long term debt | $2.63 | $1 | ||
| Total current liabilities | $14.3 | $13.12 | $16.19 | $12.79 |
| Long term debt | $15.71 | $15.28 | $15.21 | $15.1 |
| Total noncurrent liabilities | $15.71 | $15.46 | $15.21 | $15.12 |
| Total debt | $18.34 | $16.46 | $15.21 | $15.1 |
| Total liabilities | $30.01 | $28.58 | $31.41 | $27.9 |
| Shareholders' equity | ||||
| Retained earnings | -$514.39 | -$489.43 | -$464.4 | -$441.43 |
| Other shareholder equity | $75.37 | |||
| Total shareholder equity | $53 | $75.37 | $98.09 | $118.34 |
| (in millions $) | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $92.85 | $190.06 | $260.17 | $187.04 |
| Short term investments | ||||
| Net receivables | $0.27 | $2.7 | $2.6 | $1.9 |
| Inventory | ||||
| Total current assets | $99.96 | $199.15 | $267.24 | $195.7 |
| Long term investments | ||||
| Property, plant & equipment | $3.95 | $4.13 | $3.06 | $3.7 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $3.99 | $4.69 | $3.99 | $4.81 |
| Total investments | ||||
| Total assets | $103.95 | $203.84 | $271.23 | $200.51 |
| Current liabilities | ||||
| Accounts payable | $0.38 | $3.49 | $2.68 | $3.95 |
| Deferred revenue | ||||
| Short long term debt | $1 | |||
| Total current liabilities | $13.12 | $19.39 | $16.61 | $14.02 |
| Long term debt | $15.28 | $14.95 | ||
| Total noncurrent liabilities | $15.46 | $14.97 | $0.28 | $0.48 |
| Total debt | $16.46 | $14.95 | ||
| Total liabilities | $28.58 | $34.36 | $16.89 | $14.5 |
| Shareholders' equity | ||||
| Retained earnings | -$489.43 | -$383.54 | -$264.42 | -$144.7 |
| Other shareholder equity | $75.37 | $169.48 | ||
| Total shareholder equity | $75.37 | $169.48 | $254.34 | $186.01 |
| (in millions $) | 1 May 2023 | 31 Dec 2022 | 30 Sep 2022 | 30 Jun 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $18.14 | $15.92 | $18.88 | |
| Selling, general & administrative | $7.12 | $7.07 | $8.9 | |
| Total operating expenses | $25.26 | $22.98 | $27.77 | |
| Operating income | -$25.26 | -$22.98 | -$27.77 | |
| Income from continuing operations | ||||
| EBIT | -$25.28 | -$23.08 | -$27.77 | |
| Income tax expense | ||||
| Interest expense | -$0.24 | -$0.11 | $0.28 | |
| Net income | ||||
| Net income | -$25.03 | -$22.97 | -$28.05 | |
| Income (for common shares) | -$25.03 | -$22.97 | -$28.05 | |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $72.19 | $83.11 | $87.24 | $54.97 |
| Selling, general & administrative | $33.25 | $35.73 | $32.99 | $20.84 |
| Total operating expenses | $105.43 | $118.84 | $120.23 | $75.81 |
| Operating income | -$105.43 | -$118.84 | -$120.23 | -$75.81 |
| Income from continuing operations | ||||
| EBIT | -$105.59 | -$119.35 | -$119.71 | -$72.97 |
| Income tax expense | ||||
| Interest expense | $0.3 | -$0.22 | ||
| Net income | ||||
| Net income | -$105.89 | -$119.13 | -$119.71 | -$72.97 |
| Income (for common shares) | -$105.89 | -$119.13 | -$119.71 | -$72.97 |
| (in millions $) | 31 Mar 2023 | 31 Dec 2022 | 30 Sep 2022 | 30 Jun 2022 |
|---|---|---|---|---|
| Net income | -$24.96 | -$25.03 | -$22.97 | -$28.05 |
| Operating activities | ||||
| Depreciation | $0.92 | $3.06 | $0.35 | $0.35 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $2.53 | $2.25 | $2.66 | $3.23 |
| Total cash flows from operations | -$20.28 | -$23.67 | -$16.41 | -$29.11 |
| Investing activities | ||||
| Capital expenditures | -$0.01 | -$0.09 | -$0.15 | |
| Investments | ||||
| Total cash flows from investing | -$0.01 | -$0.09 | -$0.15 | |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.06 | $0.06 | $0.06 | $0 |
| Net borrowings | ||||
| Total cash flows from financing | $0.06 | $0.06 | $0.06 | $0 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$20.24 | -$23.61 | -$16.44 | -$29.25 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Net income | -$105.89 | -$119.13 | -$119.71 | -$72.97 |
| Operating activities | ||||
| Depreciation | $4.17 | $1.4 | $1.21 | $0.85 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $11.52 | $18.58 | $15.63 | $6.8 |
| Total cash flows from operations | -$97.21 | -$98.03 | -$98.8 | -$67.67 |
| Investing activities | ||||
| Capital expenditures | -$0.27 | -$2.46 | -$1.18 | -$1.58 |
| Investments | ||||
| Total cash flows from investing | -$0.27 | -$2.46 | -$1.18 | -$1.58 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.26 | $15.47 | $172.62 | $129.99 |
| Net borrowings | $14.9 | |||
| Total cash flows from financing | $0.26 | $30.37 | $172.62 | $129.99 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$97.21 | -$70.11 | $72.64 | $60.74 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 0.38 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 5.40 |
| Quick ratio | 5.40 |